CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lenalidomide
Drug: Temsirolimus
Drug: Quinidine
Drug: Diphenhydramine

First Posted Date: 2012-10-24

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 31

Registration Number: NCT01712828

Locations: 🇺🇸
Covance Clinical Research Unit Dallas, Dallas, Texas, United States

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2012-10-24

Last Posted Date: 2022-01-10

Lead Sponsor: Celgene

Target Recruit Count: 682

Registration Number: NCT01712789

Locations: 🇦🇹
Medical University of Graz, Graz, Austria
🇦🇹
Medizinische Universitat Innsbruck, Innsbruck, Austria
🇦🇹
Wilhelminenspital Vienna, Vienna, Austria

and more 109 locations

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy
Pharmacology, Clinical

Interventions: Drug: Pomalidomide
Drug: Ketoconazole
Drug: Carbamazepine
Drug: Fluvoxamine

First Posted Date: 2012-10-16

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT01707407

Locations: 🇺🇸
Covance Research Unit, Inc, Madison, Wisconsin, United States

A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: dexamethasone

First Posted Date: 2012-10-03

Last Posted Date: 2018-11-08

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT01698801

Locations: 🇯🇵
Iwate Medical University, Morioka, Iwate, Japan
🇯🇵
Tokai University Hospital, Isehara, Kanagawa, Japan
🇯🇵
National Disaster Medical Center, Tachikawa, Tokyo, Japan

and more 21 locations

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 50 mg AVL-292
Drug: 100 mg AVL-292
Drug: 200 mg AVL-292
Drug: 350 mg AVL-292
Drug: Placebo capsules

First Posted Date: 2012-09-25

Last Posted Date: 2019-11-04

Lead Sponsor: Celgene

Target Recruit Count: 54

Registration Number: NCT01692184

Locations: 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States

Connect® Myeloid Disease Registry

Recruiting

Conditions: Primary Myelofibrosis
Myelodysplastic Syndromes
Leukemia, Myeloid, Acute

Interventions: Drug: Luspatercept

First Posted Date: 2012-09-19

Last Posted Date: 2024-05-02

Lead Sponsor: Celgene

Target Recruit Count: 2300

Registration Number: NCT01688011

Locations: 🇺🇸
Local Institution - 1088, Cleveland, Ohio, United States
🇺🇸
Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸
TriHealth, Good Samaritan Hospital, Cincinnati, Ohio, United States

and more 236 locations

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: pegylated liposomal doxorubicin (PLD)
Drug: Placebo
Drug: VTX-2337

First Posted Date: 2012-08-16

Last Posted Date: 2019-09-26

Lead Sponsor: Celgene

Target Recruit Count: 297

Registration Number: NCT01666444

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Aspirus Regional Cancer Center, Wausau, Wisconsin, United States
🇺🇸
Johns Hopkins Medical Institution, Baltimore, Maryland, United States

and more 124 locations

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Ozanimod
Drug: Placebo

First Posted Date: 2012-07-23

Last Posted Date: 2021-05-19

Lead Sponsor: Celgene

Target Recruit Count: 199

Registration Number: NCT01647516

Locations: 🇸🇰
Slovak Research Center, Ilava, Slovakia
🇧🇬
University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria
🇧🇬
University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria

and more 85 locations

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma

First Posted Date: 2012-07-03

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Registration Number: NCT01632826

Locations: 🇨🇦
Celgene Study Site, Saskatoon, Saskatchewan, Canada

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Phase 2

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Ozanimod
Drug: Placebo

First Posted Date: 2012-06-26

Last Posted Date: 2021-02-11

Lead Sponsor: Celgene

Target Recruit Count: 258

Registration Number: NCT01628393

Locations: 🇧🇪
Centre Hospitalier Chretien Clinique Saint Joseph, Montegnee, Belgium
🇧🇪
Clinique Saint-Pierre, Ottignies, Belgium
🇧🇪
Cliniques Universitaires St-Luc, Brussels, Belgium

and more 55 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy